



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance.

- Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.)
- Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified.
- PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc.
- The use of pharmaceutical samples will not be considered when evaluating the members' medical condition or prior prescription history for drugs that require prior authorization.
- Quantity limits may apply. (Medicaid MCOs are required to follow only the limits that are specified on the PDL document.) Refer to the Medicaid Fee-for-Service Limits List at <http://www.dhhr.wv.gov/bms/Pharmacy/Documents/DrugLimitationSummary.pdf>
- Acronyms
 - CL - Requires clinical PA. For detailed clinical criteria, please refer to: <http://www.dhhr.wv.gov/bms/Pharmacy/Pages/pac.aspx>
 - NR - New drug has not been reviewed by P & T Committee
 - AP - Non-preferred and selected preferred drugs, where indicated, are subject to auto-PA criteria. See PA criteria column.



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACNE AGENTS (Topical)^{AP}			
ANTI-INFECTIVE			
	AZELEX (azelaic acid) clindamycin gel, lotion, medicated swab, solution erythromycin gel, solution sulfacetamide suspension	ACZONE (dapsons) AKNE-MYCIN (erythromycin) CLEOCIN-T (clindamycin) CLINDACIN PAC (clindamycin) CLINDAGEL (clindamycin) clindamycin foam erythromycin medicated swab EVOCLIN (clindamycin) KLARON (sulfacetamide) OVACE/PLUS (sulfacetamide) sulfacetamide cleanser	Thirty (30) day trials each of one (1) preferred retinoid and two (2) unique chemical entities in two (2) other subclasses, including the generic version of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. (In cases of pregnancy, a trial of retinoids will not be required.)
RETINOIDS			
	TAZORAC (tazarotene) tretinoin cream, gel	adapalene ATRALIN (tretinoin) AVITA (tretinoin) DIFFERIN (adapalene) RETIN-A (tretinoin) RETIN A MICRO (tretinoin) tretinoin gel micro ^{NR} TRETIN-X (tretinoin)	PA required for members eighteen (18) years of age or older for tretinoin products.
KERATOLYTICS			
	benzoyl peroxide cleanser Rx & OTC, 10% cream OTC, gel Rx & OTC, lotion OTC, wash OTC	ACNE CLEARING SYSTEM (benzoyl peroxide/skin cleanser) ^{NR} BENZEFOAM (benzoyl peroxide) BENZEFOAM ULTRA (benzoyl peroxide) BENZEPRO (benzoyl peroxide) benzoyl peroxide cloths, foam, medicated pads, microspheres cleanser BP wash 7% (benzoyl peroxide) BP 10-1 (benzoyl peroxide) DELOS (benzoyl peroxide) DESQUAM-X (benzoyl peroxide) LAVOCLEN (benzoyl peroxide) PACNEX/HP/LP (benzoyl peroxide) PANOXYL-4, -8 OTC (benzoyl peroxide) PERSA-GEL OTC (benzoyl peroxide)	Acne kits are non-preferred.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		SASTID (sulfur) SULPHO-LAC (sulfur)	
COMBINATION AGENTS			
	erythromycin/benzoyl peroxide sulfacetamide solution sulfacetamide/sulfur wash/cleanser	ACANYA (clindamycin phosphate/benzoyl peroxide) AVAR/-E/LS (sulfur/sulfacetamide) BENZACLIN GEL (benzoyl peroxide/clindamycin) BENZAMYCIN PAK (benzoyl peroxide/erythromycin) benzoyl peroxide/clindamycin gel benzoyl peroxide/urea CERISA (sulfacetamide sodium/sulfur) CLARIFOAM EF (sulfacetamide/sulfur) CLENIA (sulfacetamide sodium/sulfur) DUAC (benzoyl peroxide/clindamycin) EPIDUO (adapalene/benzoyl peroxide) INOVA 4/1, 5/2 (benzoyl peroxide/salicylic acid) NUOX (benzoyl peroxide/sulfur) PRASCION (sulfacetamide sodium/sulfur) SE 10-5 SS (sulfacetamide/sulfur) SSS 10-4 (sulfacetamide /sulfur) SSS 10-5 foam (sulfacetamide /sulfur)^{NR} sulfacetamide sodium/sulfur cloths, lotion, pads, suspension sulfacetamide/sulfur wash kit^{NR} sulfacetamide sodium/sulfur/ urea SUMADAN (sulfacetamide/sulfur) SUMAXIN/TS (sulfacetamide sodium/sulfur) TL TRISEB CREAM^{NR} VELTIN (clindamycin/tretinoin) ZIANA (clindamycin/tretinoin)	Thirty (30) day trials each of one (1) preferred retinoid and two (2) unique chemical entities in two (2) other subclasses, including the generic version of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. (In cases of pregnancy, a trial of retinoids will not be required.) In addition, thirty (30) day trials of combinations of the corresponding preferred single agents available are required before non-preferred combination agents will be authorized.
ALZHEIMER'S AGENTS^{AP}			
CHOLINESTERASE INHIBITORS			
	donepezil	ARICEPT (donepezil) EXELON CAPSULE (rivastigmine)	A thirty (30) day trial of a preferred agent is required before a non-



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		EXELON PATCH (rivastigmine) galantamine galantamine ER RAZADYNE (galantamine) RAZADYNE ER (galantamine) rivastigmine	<p>preferred agent in this class will be authorized unless one (1) of the exceptions on the PA form is present.</p> <p>Prior authorization is required for members up to forty-five (45) years of age if there is no diagnosis of Alzheimer's disease.</p> <p>Aricept 23mg tablets will be approved when there is a diagnosis of moderate-to-severe Alzheimer's Disease, a trial of donepezil 10mg daily for at least three (3) months, and donepezil 20mg daily for an additional one (1) month.</p>
NMDA RECEPTOR ANTAGONIST			
	NAMENDA (memantine)	NAMENDA XR (memantine) ^{NR}	
ANALGESICS, NARCOTIC - SHORT ACTING (Non-parenteral)^{AP}			
	APAP/codeine butalbital/APAP/caffeine/codeine codeine hydrocodone/APAP hydrocodone/ibuprofen hydromorphone tablets morphine oxycodone oxycodone/APAP oxycodone/ASA pentazocine/APAP pentazocine/naloxone ROXICET SOLUTION (oxycodone/ acetaminophen) ROXICODONE TABLETS (oxycodone) tramadol tramadol/APAP	ABSTRAL (fentanyl) ACTIQ (fentanyl) butalbital/ASA/caffeine/codeine butorphanol CAPITAL W/ CODEINE (APAP/codeine) DEMEROL (meperidine) dihydrocodeine/ APAP/caffeine dihydrocodeine/ASA/ caffeine ^{NR} DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl) FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) hydromorphone liquid hydromorphone suppositories LAZANDA (fentanyl) levorphanol LORCET (hydrocodone/APAP) LORTAB (hydrocodone/APAP)	<p>Six (6) day trials of at least four (4) chemically distinct preferred agents (based on narcotic ingredient only), including the generic formulation of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.</p> <p>Fentanyl lozenges and Onsolis will only be approved for a diagnosis of cancer and as an adjunct to a long-acting agent. Neither will be approved for monotherapy.</p> <p>Limits: Unless the patient has escalating cancer pain or another diagnosis supporting increased quantities of short-acting opioids, all short acting solid forms of the</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		MAXIDONE ((hydrocodone/APAP) MAGNACET (oxycodone/APAP) Meperidine NORCO (hydrocodone/APAP) NUCYNTA (tapentadol) ONSOLIS (fentanyl) OPANA (oxymorphone) OXECTA (oxycodone) oxycodone/ASA oxycodone/ibuprofen OXYIR (oxycodone) oxymorphone PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/ASA) PRIMLEV (oxycodone/APAP) REPRESXAIN (hydrocodone/ibuprofen) RYBIX ODT (tramadol) SUBSYS (fentanyl) SYNALGOS-DC (dihydrocodeine/ASA/ caffeine) TREZIX (dihydrocodeine/ APAP/caffeine) TYLENOL W/CODEINE (APAP/codeine) TYLOX (oxycodone/APAP) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen) VOPAC (codeine/acetaminophen) XODOL (hydrocodone/acetaminophen) XOLOX (oxycodone/APAP) ZAMICET (hydrocodone/APAP) ZYDONE (hydrocodone/acetaminophen)	narcotic analgesics are limited to 120 tablets per thirty (30) days for the purpose of maximizing the use of longer acting medications to prevent unnecessary breakthrough pain in chronic pain therapy. Immediate-release tramadol is limited to 240 tablets per thirty (30) days.
ANALGESICS, NARCOTIC - LONG ACTING (Non-parenteral)^{AP}			
	fentanyl transdermal methadone morphine ER tablets	AVINZA (morphine) BUTRANS (buprenorphine) CONZIP ER (tramadol) DOLOPHINE (methadone) DURAGESIC (fentanyl) EXALGO ER (hydromorphone) EMBEDA (morphine/naltrexone) KADIAN (morphine) morphine ER capsules	Six (6) day trials each of two (2) preferred unique long acting chemical entities are required before a non-preferred agent will be approved unless one (1) of the exceptions on the PDL form is present. The generic form of the requested non-preferred agent, if available, must be tried before the



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		MS CONTIN (morphine) NUCYNTA ER (tapentadol) OPANA ER (oxymorphone) ORAMORPH SR (morphine) oxycodone ER OXYCONTIN (oxycodone) oxymorphone ER RYZOLT ER (tramadol) tramadol ER ULTRAM ER (tramadol)	<p>non-preferred agent will be approved.</p> <p>Butrans will be approved if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderate to severe chronic pain requiring continuous around-the-clock analgesia and 2. Patient cannot take oral medications and has a diagnosis of chronic pain and 3. Needs analgesic medication for an extended period of time and 4. Has had a previous trial** of a non-opioid analgesic medication and 5. Previous trial of one (1) opioid medication** and 6. Current total daily opioid dose is ≤ 80mg morphine equivalents daily or dose of transdermal fentanyl is ≤ 12.5mcg/hr and 7. Patient is not currently being treated with buprenorphine. <p>**Requirement is waived for patients who cannot swallow</p> <p>Exception: Oxycodone ER and oxymorphone ER will be authorized without a trial of the preferred agents if a diagnosis of cancer is submitted.</p>
ANALGESICS (Topical)^{AP}			
	lidocaine lidocaine/prilocaine xylocaine	EMLA (lidocaine/prilocaine) FLECTOR PATCH (diclofenac) LIDAMANTLE (lidocaine) LIDAMANTLE HC (lidocaine/hydrocortisone) PENNSAID (diclofenac) SYNERA (lidocaine/tetracaine) VOLTAREN GEL (diclofenac)	Ten (10) day trials of each of the preferred topical anesthetics (lidocaine, lidocaine/prilocaine, and xylocaine) are required before a non-preferred topical anesthetic will be approved unless one (1) of the exceptions on the PA form is



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<p>present.</p> <p>Thirty (30) day trials of each of the preferred oral NSAIDs and capsaicin are required before Voltaren Gel will be approved unless one (1) of the exceptions on the PA form is present.</p> <p>Flector patches will be approved only for a diagnosis of acute strain, sprain or injury after a five (5) day trial of one (1) of the preferred oral NSAIDs and for a maximum duration of fourteen (14) days unless one (1) of the exceptions on the PA form is present.</p>
ANDROGENIC AGENTS			
	ANDRODERM (testosterone) ANDROGEL (testosterone)	AXIRON (testosterone) FORTESTA (testosterone) TESTIM (testosterone)	The non-preferred agents will be approved only if one (1) of the exceptions on the PA form is present.
ANGIOTENSIN MODULATORS^{AP}			
ACE INHIBITORS			
	benazepril captopril enalapril fosinopril lisinopril quinapril ramipril	ACCUPRIL (quinapril) ACEON (perindopril) ALTACE (ramipril) LOTENSIN (benazepril) MAVIK (trandolapril) moexipril perindopril PRINIVIL (lisinopril) trandolapril UNIVASC (moexipril) VASOTEC (enalapril) ZESTRIL (lisinopril)	Fourteen (14) day trials of each of the preferred agents in the corresponding group, with the exception of the Direct Renin Inhibitors, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
ACE INHIBITOR COMBINATION DRUGS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	benazepril/amlodipine benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LOTENSIN HCT (benazepril/HCTZ) LOTREL (benazepril/amlodipine) moexipril/HCTZ PRINZIDE (lisinopril/HCTZ) TARKA (trandolapril/verapamil) trandolapril/verapamil UNIRETIC (moexipril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)			
	BENICAR (olmesartan) DIOVAN (valsartan) irbesartan losartan MICARDIS (telmisartan)	ATACAND (candesartan) AVAPRO (irbesartan) candesartan ^{NR} COZAAR (losartan) EDARBI (azilsartan) eprosartan TEVETEN (eprosartan)	
ARB COMBINATIONS			
	BENICAR-HCT (olmesartan/HCTZ) DIOVAN-HCT (valsartan/HCTZ) EXFORGE (valsartan/amlodipine) EXFORGE HCT (valsartan/amlodipine/HCTZ) irbesartan/HCTZ losartan/HCTZ MICARDIS-HCT (telmisartan/HCTZ)	ATACAND-HCT (candesartan/HCTZ) AVALIDE (irbesartan/HCTZ) AZOR (olmesartan/amlodipine) candesartan/HCTZ EDARBYCLOR (azilsartan/chlorthalidone) HYZAAR (losartan/HCTZ) TEVETEN-HCT (eprosartan/HCTZ) TRIBENZOR (olmesartan/amlodipine/HCTZ) TWYNSTA (telmisartan/amlodipine) valsartan/HCTZ	
DIRECT RENIN INHIBITORS			
		AMTURNIDE (aliskiren/amlodipine/HCTZ) TEKAMLO (aliskiren/amlodipine) TEKTURNA (aliskiren) TEKTURNA HCT (aliskiren/HCTZ) VALTURNA (aliskiren/valsartan)	<p>A thirty (30) day trial of one (1) preferred ACE, ARB, or combination agents, at the maximum tolerable dose, is required before Tekturma will be approved.</p> <p>Tekturma HCT, Valturma, Tekamlo or Amturnide will be approved if the criteria for Tekturma are met and the patient also needs the other agents</p>



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			in the combination.
ANTIBIOTICS, GI	metronidazole tablet NEO-FRADIN (neomycin) neomycin TINDAMAX (tinidazole)	ALINIA (nitazoxanide) DIFICID (fidaxomicin) FLAGYL (metronidazole) FLAGYL ER (metronidazole ER) metronidazole capsule paromomycin tinidazole VANCOCIN (vancomycin) vancomycin XIFAXAN (rifaximin)	<p>A fourteen (14) day trial of a corresponding generic preferred agent is required before a non-preferred brand agent will be approved.</p> <p>Dificid will be approved if:</p> <ol style="list-style-type: none"> 1. There is a diagnosis of severe <i>C. difficile</i> infection and 2. There is no response to prior treatment with vancomycin for ten (10) to fourteen (14) days. <p>Xifaxan 200mg will be approved for traveler's diarrhea if 1) there is a diagnosis of <i>E. coli</i> diarrhea, 2) patient is from twelve (12) up to eighteen (18) years of age, or is eighteen (18) years of age or older and has failed a ten (10) day trial of ciprofloxacin.</p> <p>Xifaxan 550mg will be approved for hepatic encephalopathy if:</p> <ol style="list-style-type: none"> 1. There is a diagnosis of hepatic encephalopathy and 2. Patient is eighteen (18) years of age or older, and 3. Patient has a history of and current treatment with lactulose. <p>Vancocin will be approved after a fourteen (14) day trial of metronidazole for <i>C. difficile</i> infections of mild to moderate severity unless one (1) of the exceptions on the PA form is present.</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIBIOTICS, INHALED			Vancocin will be approved for severe <i>C. difficile</i> infections with no previous trial of metronidazole.
	TOBI (tobramycin)	CAYSTON (aztreonam) TOBI PODHALER^{NR}	A twenty-eight (28) day trial of the preferred agent is required before the non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present.
ANTICOAGULANTS			
INJECTABLE^{CL}			
	FRAGMIN (dalteparin) LOVENOX (enoxaparin)	ARIXTRA (fondaparinux) enoxaparin fondaparinux INNOHEP (tinzaparin)	Trials of each of the preferred agents will be required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present.
ORAL			
	COUMADIN (warfarin) PRADAXA (dabigatran) ^{AP} warfarin XARELTO (rivaroxaban) ^{AP}	ELIQUIS (apixaban)	Pradaxa will be approved for the diagnosis of non-valvular atrial fibrillation. Xarelto will be approved for the following diagnoses: 1. Non-valvular atrial fibrillation or 2. Deep vein thrombosis (DVT), pulmonary embolism (PE), and reduction in risk of recurrence of DVT and PE or 3. DVT prophylaxis if treatment is limited to thirty-five (35) days for hip replacement surgeries or twelve (12) days for knee replacement surgeries.
ANTICONVULSANTS			
ADJUVANTS			



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	carbamazepine carbamazepine ER carbamazepine XR CARBATROL (carbamazepine) DEPAKOTE SPRINKLE (divalproex) divalproex divalproex ER EPITOL (carbamazepine) FELBATOL (felbamate) GABITRIL (tiagabine) lamotrigine levetiracetam oxcarbazepine tablets TEGRETOL XR (carbamazepine) topiramate TRILEPTAL SUSPENSION (oxcarbazepine) valproic acid zonisamide	BANZEL(rufinamide) DEPAKENE (valproic acid) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) divalproex sprinkle EQUETRO (carbamazepine) FANATREX SUSPENSION (gabapentin) felbamate KEPBRA (levetiracetam) KEPBRA XR (levetiracetam) LAMICTAL (lamotrigine) LAMICTAL CHEWABLE (lamotrigine) LAMICTAL ODT (lamotrigine) LAMICTAL XR (lamotrigine) lamotrigine dose pack lamotrigine ER levetiracetam ER ONFI (clobazam) oxcarbazepine suspension OXTELLAR XR (oxcarbazepine) POTIGA (ezogabine) SABRIL (vigabatrin) STAVZOR (valproic acid) TEGRETOL (carbamazepine) tiagabine TOPAMAX (topiramate) TRILEPTAL TABLETS (oxcarbazepine) VIMPAT (lacosamide) ZONEGRAN (zonisamide)	<p>A fourteen (14) day trial of one (1) of the preferred agents in the corresponding group is required for treatment naïve patients with a diagnosis of a seizure disorder before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.</p> <p>A thirty (30) day trial of one (1) of the preferred agents in the corresponding group is required for patients with a diagnosis other than seizure disorders unless one (1) of the exceptions on the PA form is present.</p> <p>Non-preferred anticonvulsants will be approved for patients on established therapies with a diagnosis of seizure disorders with no trials of preferred agents required. In situations where AB-rated generic equivalent products are available, "Brand Medically Necessary" must be hand-written by the prescriber on the prescription in order for the brand name product to be reimbursed.</p> <p>Requests for Onfi will be authorized if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Adjunctive therapy for Lennox-Gastaut or 2. Generalized tonic, atonic or myoclonic seizures and 3. Previous failure of at least two (2) non-benzodiazepine anticonvulsants and previous failure of clonazepam. <p>(For continuation, prescriber must include information regarding</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			improved response/effectiveness with this medication)
	BARBITURATES^{AP}		
	phenobarbital primidone	MEBARAL (mephobarbital) MYSOLINE (primidone)	
	BENZODIAZEPINES^{AP}		
	clonazepam DIASTAT (diazepam rectal) diazepam tablets	clonazepam ODT diazepam rectal gel KLONOPIN (clonazepam)	
	HYDANTOINS^{AP}		
	DILANTIN 30mg (phenytoin) PEGANONE (ethotoin) phenytoin capsules, chewable tablets, suspension	DILANTIN (phenytoin) DILANTIN INFATABS (phenytoin) PHENYTEK (phenytoin)	
	SUCCINIMIDES		
	CELONTIN (methsuximide) ethosuximide syrup ZARONTIN (ethosuximide) capsules	ethosuximide capsules ZARONTIN (ethosuximide) syrup	
ANTIDEPRESSANTS, OTHER			
	MAOIs^{AP}		
	PARNATE (tranylcypromine) phenelzine	MARPLAN (isocarboxazid) NARDIL (phenelzine) tranylcypromine	A thirty (30) day trial of a preferred agent is required before a non-preferred agent will be approved. Patients stabilized on non-preferred agents will be grandfathered.
	SNRIS^{AP}		
	venlafaxine ER capsules	desvenlafaxine ER ^{NR} EFFEXOR XR (venlafaxine) PRISTIQ (desvenlafaxine) venlafaxine IR VENLAFAXINE ER TABLETS (venlafaxine)	A six (6) week trial each of a preferred agent and an SSRI is required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			form is present.
SECOND GENERATION NON-SSRI, OTHER^{AP}			
	bupropion IR bupropion SR bupropion XL mirtazapine trazodone	APLENZIN (bupropion hbr) EMSAM (selegiline) FORFIVO XL (bupropion) nefazodone OLEPTRO ER (trazodone) REMERON (mirtazapine) WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion) VIIBRYD (vilazodone hcl)	
SELECTED TCAs			
	imipramine hcl	imipramine pamoate TOFRANIL (imipramine hcl) TOFRANIL PM (imipramine pamoate)	A twelve (12) week trial of imipramine hcl is required before a non-preferred TCA will be authorized.
ANTIDEPRESSANTS, SSRIs^{AP}			
	citalopram escitalopram tablets fluoxetine capsules, solution fluvoxamine paroxetine sertraline	CELEXA (citalopram) escitalopram solution fluvoxamine ER ^{NR} fluoxetine tablets LEXAPRO (escitalopram) LUVOX CR (fluvoxamine) PAXIL (paroxetine) PAXIL CR (paroxetine) paroxetine ER PEXEVA (paroxetine) PROZAC (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	Thirty (30) day trials each of two (2) of the preferred agents are required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present. Upon hospital discharge, patients admitted with a primary mental health diagnosis and have been stabilized on a non-preferred SSRI will receive an authorization to continue that drug.
ANTIEMETICS^{AP}			
5HT3 RECEPTOR BLOCKERS			
	ondansetron ODT, solution, tablets	ANZEMET (dolasetron) granisetron GRANISOL (granisetron) ondansetron vials SANCUSO (granisetron)	A three (3) day trial of a preferred agent is required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. PA is



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		ZOFRAN (ondansetron) ZUPLENZ (ondansetron)	required for ondansetron when limits are exceeded.
CANNABINOIDS			
		CESAMET (nabilone) dronabinol MARINOL (dronabinol)	Cesamet will be authorized only for the treatment of nausea and vomiting associated with cancer chemotherapy for patients who have failed to respond adequately to three (3) day trials of conventional treatments such as promethazine or ondansetron and are eighteen (18) years of age or older. Marinol will be authorized only for: 1. The treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol or 2. The prophylaxis of chemotherapy induced nausea and vomiting unresponsive to three (3) day trials of ondansetron or promethazine for patients from eighteen (18) up to sixty-five (65) years of age.
SUBSTANCE P ANTAGONISTS			
	EMEND (aprepitant)		
ANTIFUNGALS (Oral)			
	clotrimazole fluconazole* ketoconazole nystatin terbinafine ^{CL}	ANCOBON (flucytosine) DIFLUCAN (fluconazole) flucytosine GRIFULVIN V TABLET (griseofulvin) griseofulvin GRIS-PEG (griseofulvin) itraconazole	Non-preferred agents will be approved only if one (1) of the exceptions on the PA form is present. *PA is required when limits are



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		LAMISIL (terbinafine) MYCELEX (clotrimazole) MYCOSTATIN Tablets (nystatin) NIZORAL (ketoconazole) NOXAFIL (posaconazole) ONMEL (itraconazole) ORAVIG (miconazole) SPORANOX (itraconazole) VFEND (voriconazole) voriconazole	exceeded. PA is not required for griseofulvin suspension for children up to six (6) years of age for the treatment of tinea capitis.
ANTIFUNGALS (Topical)^{AP}			
ANTIFUNGALS			
	econazole ketoconazole cream, shampoo MENTAX (butenafine) miconazole (OTC) NAFTIN CREAM (naftifine) nystatin	CICLODAN (ciclopirox) ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) EXTINA (ketoconazole) ketoconazole foam KETODAN (ketoconazole) LOPROX (ciclopirox) MYCOSTATIN (nystatin) NAFTIN GEL (naftifine) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PEDIPIROX-4 (ciclopirox) PENLAC (ciclopirox) VUSION (miconazole/petrolatum/zinc oxide) XOLEGEL (ketoconazole)	Fourteen (14) day trials of two (2) of the preferred agents are required before one (1) of the non-preferred agents will be authorized unless one (1) of the exceptions on the PA form is present. If a non-preferred shampoo is requested, a fourteen (14) day trial of one (1) preferred product (ketoconazole shampoo) is required. Oxistat cream will be approved for children up to thirteen (13) years of age for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor.
ANTIFUNGAL/STEROID COMBINATIONS			
	clotrimazole/betamethasone nystatin/triamcinolone	KETOCON PLUS (ketoconazole/hydrocortisone) LOTRISONE (clotrimazole/betamethasone) ^{AP}	
ANTI-HISTAMINES, MINIMALLY SEDATING^{AP}			
ANTI-HISTAMINES			
	cetirizine tablets, solution loratadine	ALLEGRA (fexofenadine) cetirizine chewable tablets cetirizine capsules ^{NR} CLARINEX (desloratadine)	Thirty (30) day trials of at least two (2) chemically distinct preferred agents (in the age appropriate form), including the generic



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		CLARITIN (loratadine) desloratadine desloratadine ODT fexofenadine levocetirizine XYZAL (levocetirizine) ZYRTEC (cetirizine)	formulation of a requested non-preferred product, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
ANTIHISTAMINE/DECONGESTANT COMBINATIONS			
	cetirizine/pseudoephedrine loratadine/pseudoephedrine SEMPREX-D (acrivastine/ pseudoephedrine)	ALLEGRA-D (fexofenadine/ pseudoephedrine) CLARINEX-D (desloratadine/ pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) fexofenadine/ pseudoephedrine ZYRTEC-D (cetirizine/pseudoephedrine)	
ANTIMIGRAINE AGENTS, TRIPTANS^{AP}			
TRIPTANS			
	IMITREX NASAL SPRAY (sumatriptan) IMITREX INJECTION (sumatriptan) ^{CL} naratriptan sumatriptan tablets	AMERGE (naratriptan) AXERT (almotriptan) FROVA (frovatriptan) IMITREX tablets (sumatriptan) MAXALT (rizatriptan) MAXALT MLT (rizatriptan) RELPAX (eletriptan) rizatriptan rizatriptan ODT sumatriptan nasal spray/injection* SUMAVEL (sumatriptan) zolmitriptan ^{NR} zolmitriptan ODT ^{NR} ZOMIG (zolmitriptan) ZOMIG ZMT (zolmitriptan)	Three (3) day trials of each unique chemical entity of the preferred agents are required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present. Quantity limits apply for this drug class. Three (3) day trials of each preferred agent will be required for Imitrex injection. *AP does not apply to nasal spray or injectable sumatriptan.
TRIPTAN COMBINATIONS			
		TREXIMET (sumatriptan/naproxen sodium)	
ANTIPARKINSON'S AGENTS (Oral)			
ANTICHOLINERGICS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	benztropine trihexyphenidyl	COGENTIN (benztropine)	Patients starting therapy on drugs in this class must show a documented allergy to all of the preferred agents, in the corresponding class, before a non-preferred agent will be authorized.
COMT INHIBITORS			
		COMTAN (entacapone) entacapone TASMAR (tolcapone)	
DOPAMINE AGONISTS			
	pramipexole ropinirole	MIRAPEX (pramipexole) MIRAPEX ER (pramipexole) NEUPRO (rotigotine) REQUIP (ropinirole) REQUIP XL (ropinirole) ropinirole ER	
OTHER ANTIPARKINSON'S AGENTS			
	amantadine ^{AP} bromocriptine carbidopa/levodopa selegiline STALEVO (levodopa/carbidopa/entacapone)	AZILECT (rasagiline) ELDEPRYL (selegiline) levodopa/carbidopa ODT levodopa/carbidopa/entacapone LODOSYN (carbidopa) PARCOPA (levodopa/carbidopa) PARLODEL (bromocriptine) SINEMET (levodopa/carbidopa) ZELAPAR (selegiline)	Amantadine will be approved only for a diagnosis of Parkinsonism.
ANTIPSYCHOTICS, ATYPICAL			
SINGLE INGREDIENT			Preferred brands require a fourteen (14) day trial of a preferred generic agent before approval.
	clozapine FANAPT (iloperidone) ^{AP} INVEGA SUSTENNA (paliperidone)* LATUDA (lurasidone) ^{AP} quetiapine ^{AP} (25mg Tablet Only)	ABILIFY (aripiprazole) ABILIFY MAINTENA (aripiprazole)^{NR} clozapine ODT CLOZARIL (clozapine) FANAPT TITRATION PACK (iloperidone)	
			Non-preferred agents will be approved for treatment naïve patients if the following criteria have been met:



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	risperidone SAPHRIS (asenapine) ^{AP} ziprasidone	FAZACLO (clozapine) GEODON (ziprasidone) GEODON IM (ziprasidone) INVEGA (paliperidone) olanzapine olanzapine IM* RISPERDAL (risperidone) RISPERDAL CONSTA (risperidone)* SEROQUEL (quetiapine) SEROQUEL XR (quetiapine) ZYPREXA (olanzapine) ZYPREXA IM (olanzapine)* ZYPREXA RELPREVV (olanzapine)	<ol style="list-style-type: none"> 1. A fourteen (14) day trial of a preferred generic agent and 2. Two (2) fourteen (14) day trials of additional preferred products unless one (1) of the exceptions on the PA form is present. <p>Upon discharge, a hospitalized patient stabilized on a non-preferred agent may receive authorization to continue this drug for labeled indications and at recommended dosages.</p> <p>Claims for quetiapine 25mg will be approved:</p> <ol style="list-style-type: none"> 1. For a diagnosis of schizophrenia or 2. For a diagnosis of bipolar disorder or 3. When prescribed concurrently with other strengths of Seroquel in order to achieve therapeutic treatment levels. <p>Quetiapine 25mg will not be approved for use as a sedative hypnotic.</p> <p>All antipsychotic agents require prior authorization for children up to six (6) years of age.</p> <p>Abilify will be approved for children from six (6) up to seventeen (17) years of age for irritability associated with autism. Abilify will be prior authorized for MDD if the following criteria are met:</p> <ol style="list-style-type: none"> 1. The patient is eighteen (18) years of age or older and



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			2. Diagnosis of Major Depressive Disorder (MDD) and 3. Evidence of trials of appropriate therapeutic duration (thirty (30) days), at the maximum tolerable dose, of at least one (1) agent in two (2) of the following classes: SSRI, SNRI or bupropion in conjunction with Seroquel at doses of 150mg or more and 4. Prescribed in conjunction with an SSRI, SNRI, or bupropion and 5. The daily dose does not exceed 15mg *All injectable antipsychotic products require clinical prior authorization and will be approved on a case-by-case basis. Patients stabilized on Invega will be grandfathered. Upon discharge, a hospitalized patient stabilized on a non-preferred agent may receive authorization to continue this drug for labeled indications and at recommended dosages with a call to RDTP.
ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS			
		olanzapine/fluoxetine SYMBYAX (olanzapine/fluoxetine)	
ANTIVIRALS (Oral)			
ANTI HERPES			
	acyclovir valacyclovir	famciclovir FAMVIR (famciclovir) VALTREX ZOVIRAX (acyclovir)	Five (5) day trials each of the preferred agents are required before the non-preferred agents will be authorized unless one (1) of the exceptions on the PA form is present.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTI-INFLUENZA			
	RELENZA (zanamivir) TAMIFLU (oseltamivir)	amantadine ^{AP} FLUMADINE (rimantadine) rimantadine	The anti-influenza agents will be approved only for a diagnosis of influenza.
ANTIVIRALS (Topical)^{AP}			
		ABREVA (docosanol) acyclovir ointment ^{NP} DENA VIR (penciclovir) ZOVIRAX (acyclovir)	Non-preferred agents will be approved for their FDA indication(s).
ATOPIC DERMATITIS			
	ELIDEL (pimecrolimus) ^{AP}	PROTOPIC (tacrolimus)	A thirty (30) day trial of a preferred medium or high potency topical corticosteroid is required before coverage of Elidel will be considered; additionally, a thirty (30) day trial of Elidel is required before Protopic will be considered, unless one (1) of the exceptions on the PA form is present.
BETA BLOCKERS (Oral) & MISCELLANEOUS ANTIANGINALS (Oral)^{AP}			
BETA BLOCKERS			
	acebutolol atenolol betaxolol bisoprolol metoprolol metoprolol ER nadolol pindolol propranolol propranolol ER sotalol timolol	BETAPACE (sotalol) BYSTOLIC (nebivolol) CORGARD (nadolol) INDERAL LA (propranolol) INNOPRAN XL (propranolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol)	Fourteen (14) day trials each of three (3) chemically distinct preferred agents, including the generic formulation of a requested non-preferred product, are required before one (1) of the non-preferred agents will be approved unless one (1) of the exceptions on the PA form is present.
BETA BLOCKER/DIURETIC COMBINATION DRUGS			
	atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ nadolol/bendroflumethiazide	CORZIDE (nadolol/bendroflumethiazide) DUTOPROL (metoprolol ER/HCTZ ER) LOPRESSOR HCT (metoprolol/HCTZ) TENORETIC (atenolol/chlorthalidone)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	propranolol/HCTZ	ZIAC (bisoprolol/HCTZ)	
BETA- AND ALPHA-BLOCKERS			
	carvedilol labetalol	COREG (carvedilol) COREG CR (carvedilol) TRANDATE (labetalol)	
ANTIANGINALS			
		RANEXA (ranolazine) ^{AP}	Ranexa will be approved for patients with angina who are also taking a calcium channel blocker, a beta blocker, or a nitrite as single agents or a combination agent containing one (1) of these ingredients.
BLADDER RELAXANT PREPARATIONS^{AP}			
	oxybutynin IR oxybutynin ER TOVIAZ (fesoterodine) VESICARE (solifenacin)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN XL (oxybutynin) ENABLEX (darifenacin) flavoxate GELNIQUE (oxybutynin) MYRBETRIQ (mirabegron) OXYTROL (oxybutynin) SANCTURA (trospium) SANCTURA XR (trospium) tolterodine trospium trospium ER	A thirty (30) day trial each of the chemically distinct preferred agents is required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
BONE RESORPTION SUPPRESSION AND RELATED AGENTS			
BISPHOSPHONATES			
	alendronate tablets	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/ calcium) alendronate solution ^{NR} ATELVIA (risedronate) BINOSTO (alendronate) BONIVA (ibandronate) DIDRONEL (etidronate) etidronate FOSAMAX TABLETS (alendronate)	A thirty (30) day trial of the preferred agent is required before a non-preferred agent will be approved.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		FOSAMAX PLUS D (alendronate/vitamin D) ibandronate	
	OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS		
	calcitonin	EVISTA (raloxifene) FORTEO (teriparatide) FORTICAL (calcitonin) MIACALCIN (calcitonin)	Evista will be approved for postmenopausal women with osteoporosis or at high risk for invasive breast cancer.
BPH AGENTS			
	5-ALPHA-REDUCTASE (5AR) INHIBITORS		
	finasteride	AVODART (dutasteride) CIALIS 5 mg (tadalafil) PROSCAR (finasteride)	Thirty (30) day trials each of at least two (2) chemically distinct preferred agents, including the generic formulation of a requested non-preferred agent, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
	ALPHA BLOCKERS		
	doxazosin tamsulosin terazosin	alfuzosin CARDURA (doxazosin) CARDURA XL (doxazosin) FLOMAX (tamsulosin) HYTRIN (terazosin) RAPAFLO (silodosin) UROXATRAL (alfuzosin)	
	5-ALPHA-REDUCTASE (5AR) INHIBITORS/ALPHA BLOCKER COMBINATION		
		JALYN (dutasteride/tamsulosin)	Thirty (30) day trials of dutasteride and tamsulosin concurrently are required before the non-preferred agent will be approved.
BRONCHODILATORS & RESPIRATORY DRUGS			
	ANTICHOLINERGIC^{AP}		



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ATROVENT HFA (ipratropium) ipratropium SPIRIVA (tiotropium)	TUDORZA (aclidinium)	A thirty (30) day trial of tiotropium is required before a non-preferred agent will be approved.
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS^{AP}			
	COMBIVENT CFC (albuterol/ipratropium) COMBIVENT RESPIMAT (albuterol/ipratropium)	albuterol/ipratropium DUONEB (albuterol/ipratropium)	For severely compromised patients, albuterol/ipratropium will be approved if the combined volume of albuterol and ipratropium nebulas is inhibitory.
PDE4 INHIBITOR			
		DALIRESP (roflumilast)	Daliresp will be approved when the following criteria are met: 1. Patient is forty (40) years of age or older and 2. Diagnosis of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and multiple exacerbations requiring systemic glucocorticoids in the preceding six (6) months and 3. Concurrent therapy with an inhaled corticosteroid and long-acting bronchodilator and evidence of compliance and 4. No evidence of moderate to severe liver impairment (Child-Pugh Class B or C) and 5. No concurrent use with strong cytochrome P450 inducers (rifampicin, phenobarbital, carbamazepine or phenytoin).
INHALATION SOLUTION^{AP}			
	ACCUNEB (albuterol)** albuterol	BROVANA (arformoterol) levalbuterol metaproterenol PERFOROMIST (formoterol) XOPENEX (levalbuterol)	Thirty (30) day trials each of the chemically distinct preferred agents in their corresponding groups are required before a non-preferred agent in that group will be authorized unless one (1) of the exceptions on the PA form is



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			present. **No PA is required for Accuneb for children up to five (5) years of age.
	INHALERS, LONG-ACTING^{AP}		
	FORADIL (formoterol) SEREVENT (salmeterol)	ARCAPTA (indacaterol maleate)	Thirty (30) day trials each of the preferred agents are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
	INHALERS, SHORT-ACTING^{AP}		
	PROAIR HFA (albuterol) PROVENTIL HFA (albuterol)	MAXAIR (pirbuterol) VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol)	Xopenex Inhalation Solution will be approved for twelve (12) months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for concurrent diagnosis of heart disease.
	ORAL^{AP}		
	albuterol IR, ER terbutaline	metaproterenol VOSPIRE ER (albuterol)	
CALCIUM CHANNEL BLOCKERS^{AP}			
	LONG-ACTING		
	amlodipine diltiazem ER felodipine ER nifedipine ER verapamil ER	ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD, LA (diltiazem) COVERA-HS (verapamil) DILACOR XR (diltiazem) diltiazem LA DYNACIRC CR (isradipine) ISOPTIN SR (verapamil) MATZIM LA (diltiazem) nisoldipine	Fourteen (14) day trials each of the preferred agents are required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		NORVASC (amlodipine) NYMALIZE SOLUTION (nimodipine)^{NR} PLENDIL (felodipine) PROCARDIA XL (nifedipine) SULAR (nisoldipine) TIAZAC (diltiazem) verapamil ER PM VERELAN/VERELAN PM (verapamil)	
SHORT-ACTING			
	diltiazem verapamil	CALAN (verapamil) CARDIZEM (diltiazem) isradipine nicardipine nifedipine nimodipine NIMOTOP (nimodipine) PROCARDIA (nifedipine)	
CEPHALOSPORINS AND RELATED ANTIBIOTICS (Oral)^{AP}			
BETA LACTAMS AND BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS			
	amoxicillin/clavulanate IR	amoxicillin/clavulanate ER AUGMENTIN (amoxicillin/clavulanate) AUGMENTIN XR (amoxicillin/clavulanate) MOXATAG (amoxicillin)	A five (5) day trial of the preferred agent is required before a non-preferred agent is authorized unless one (1) of the exceptions on the PA form is present.
CEPHALOSPORINS			
	cefaclor cefadroxil capsule, tablet cefdinir cefuroxime tablet cephalexin capsule, suspension	CEDAX (ceftibuten) cefaclor ER tablet cefadroxil suspension cefditoren cefpodoxime cefprozil CEFTIN (cefuroxime) cefuroxime suspension cephalexin tablet KEFLEX (cephalexin) OMNICEF (cefdinir) RANICLOR (cefaclor) SPECTRACEF (cefditoren) SUPRAX CAPSULE (cefixime)^{NR}	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		SUPRAX TABLET (cefixime)	
COLONY STIMULATING FACTORS			
	LEUKINE (sargramostim) NEUPOGEN (filgrastim)	NEULASTA (filgrastim)	A thirty (30) day trial of one (1) of the preferred agents is required before the non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
CYTOKINE & CAM ANTAGONISTS^{CL}			
	ENBREL (etanercept) HUMIRA (adalimumab)	CIMZIA (certolizumab pegol) KINERET (anakinra) ORENCIA (abatacept) SIMPONI (golimumab) STELARA (ustekinumab) XELJANZ (tofacitinib)*	<p>Thirty (30) day trials of each of the preferred agents are required before a non-preferred agent will be approved.</p> <p>* Xeljanz (tofacitinib) will be approved after a thirty (30) day trial of one (1) of the preferred agents if each of the following criteria are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of moderately or severely active rheumatoid arthritis and 2. Negative tuberculin skin test before initiation of therapy and 3. Intolerance to or an inadequate response to a sixty (60) day trial of methotrexate and 4. The patient is eighteen (18) years of age or older and 5. There are no plans to use tofacitinib in combination with biologic DMARDS or potent immunosuppressants (e.g. azathioprine or cyclosporine) and 6. The dose is limited to two (2) tablets daily. <p>See additional criteria for treatment of psoriasis or psoriatic arthritis at</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			http://www.dhhr.wv.gov/bms/Pharmacy/Pages/pac.aspx
ERYTHROPOIESIS STIMULATING PROTEINS^{CL}			
	PROCRT (rHuEPO)	ARANESP (darbepoetin) EPOGEN (rHuEPO)	<p>A thirty (30) day trial of the preferred agent is required before a non-preferred agent will be approved.</p> <p>Prior authorization will be given for the erythropoiesis agents if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Hemoglobin or Hematocrit less than 10/30 respectively. For renewal, hemoglobin or hematocrit levels greater than 12/36 will require dosage reduction or discontinuation. Exceptions will be considered on an individual basis after medical documentation is reviewed. (Laboratory values must be dated within six (6) weeks of request.) and 2. Transferrin saturation \geq 20%, ferritin levels \geq100 mg/ml, or on concurrent therapeutic iron therapy. (Laboratory values must be dated within three (3) weeks of request. For re-authorization, transferrin saturation or ferritin levels are not required if the patient has been responsive to the erythropoietin agent and 3. For HIV-infected patients, endogenous serum erythropoietin level must be \leq 500mU/ml to initiate therapy and 4. No evidence of untreated GI bleeding, hemolysis, or Vitamin B-12, iron or folate deficiency.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
FLUOROQUINOLONES (Oral)^{AP}			
	CIPRO SUSPENSION (ciprofloxacin) ciprofloxacin levofloxacin tablet	AVELOX (moxifloxacin) CIPRO TABLETS (ciprofloxacin) CIPRO XR (ciprofloxacin) ciprofloxacin ER FACTIVE (gemifloxacin) FLOXIN (ofloxacin) LEVAQUIN (levofloxacin) levofloxacin solution NOROXIN (norfloxacin) ofloxacin PROQUIN XR (ciprofloxacin)	A five (5) day trial of one (1) of the preferred agents is required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present.
GENITAL WARTS AGENTS			
	ALDARA (imiquimod)	CONDYLOX (podofilox) imiquimod podofilox VEREGEN (sinecatechins) ZYCLARA (imiquimod)	A thirty (30) day trial of the preferred agent is required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. Zyclara will be approved for a diagnosis of actinic keratosis.
GLUCOCORTICOIDS (Inhaled)^{AP}			
GLUCOCORTICOIDS			
	ASMANEX (mometasone) FLOVENT HFA (fluticasone) FLOVENT Diskus (fluticasone) PULMICORT FLEXHALER (budesonide) PULMICORT RESPULES (budesonide)* QVAR (beclomethasone)	ALVESCO (ciclesonide) budesonide	Thirty (30) day trials each of the preferred agents are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. Pulmicort Respules do not require a prior authorization for children up to nine (9) years of age or for individuals unable to use an MDI. When children who have been stabilized on Pulmicort Respules reach age 9, prescriptions for the Pulmicort inhaler will be authorized for them.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			*For children up to nine (9) years of age, and for those who meet the PA requirements, brand Pulmicort is preferred over the generic.
GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS			
	ADVAIR (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol) SYMBICORT(budesonide/formoterol)	BREO ELLIPTA (fluticasone/vilanterol)^{NH}	
GLUCOCORTICOIDS (Topical)			
VERY HIGH & HIGH POTENCY			
	betamethasone dipropionate cream, lotion betamethasone valerate cream clobetasol propionate cream/gel/ointment/solution clobetasol emollient fluocinonide cream, gel, solution fluocinonide/emollient halobetasol propionate triamcinolone acetonide cream, ointment	amcinonide APEXICON (diflorasone diacetate) APEXICON E (diflorasone diacetate) betamethasone dipropionate gel, lotion, ointment betamethasone valerate lotion, ointment, clobetasol lotion, shampoo clobetasol propionate foam CLOBEX (clobetasol propionate) CORMAX (clobetasol propionate) desoximetasone cream/gel/ointment diflorasone diacetate DIPROLENE (betamethasone dipropionate/propylene glycol) DIPROLENE AF (betamethasone dipropionate/propylene glycol) DIPROSONE (betamethasone dipropionate) fluocinonide ointment halcinonide HALAC (halobetasol propionate) HALOG (halcinonide) HALONATE (halobetasol propionate) KENALOG (triamcinolone acetonide) LIDEX (fluocinonide) LIDEX-E (fluocinonide) OLUX (clobetasol propionate) OLUX-E (clobetasol propionate/emollient) PSORCON (diflorasone diacetate) TEMOVATE (clobetasol propionate)	Five (5) day trials of one (1) form of each preferred unique active ingredient in the corresponding potency group are required before a non-preferred agent will be approved.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		TEMOVATE-E (clobetasol propionate/emollient) TOPICORT CREAM, GEL, OINTMENT (desoximetasone) TOPICORT SPRAY (desoximetasone)^{NR} triamcinolone acetonide lotion ULTRAVATE (halobetasol propionate) ULTRAVATE PAC cream ULTRAVATE X (halobetasol propionate / lactic acid) VANOS (fluocinonide)	
MEDIUM POTENCY			
	fluticasone propionate cream, ointment hydrocortisone butyrate ointment, solution hydrocortisone valerate mometasone furoate triamcinolone acetonide 0.025% and 0.1% cream	ARISTOCORT (triamcinolone) BETA-VAL (betamethasone valerate) betamethasone valerate foam CLODERM (clocortolone pivalate) CORDRAN/CORDRAN SP (flurandrenolide) CUTIVATE (fluticasone propionate) DERMATOP (prednicarbate) ELOCON (mometasone furoate) fluocinolone acetonide cream, ointment, solution fluticasone propionate lotion hydrocortisone butyrate cream LOCOID (hydrocortisone butyrate) LOCOID LIPOCREAM (hydrocortisone butyrate/emollient) LUXIQ (betamethasone valerate) MOMEXIN (mometasone) PANDEL (hydrocortisone probutate) prednicarbate TOPICORT LP (desoximetasone) TRIDERM (triamcinolone acetonide) WESTCORT (hydrocortisone valerate)	
LOW POTENCY			
	desonide cream, ointment fluocinolone oil hydrocortisone acetate (Rx, OTC) hydrocortisone cream (Rx, OTC)	ACLOVATE (acclometasone dipropionate) acclometasone dipropionate AQUA GLYCOLIC HC (hydrocortisone) CAPEX (fluocinolone acetonide)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	hydrocortisone lotion OTC hydrocortisone ointment (Rx, OTC) hydrocortisone solution OTC hydrocortisone-aloe cream OTC hydrocortisone-aloe ointment OTC	DERMA-SMOOTHIE FS (fluocinolone acetonide) DESONATE (desonide) desonide lotion DESOWEN (desonide) hydrocortisone/mineral oil/petrolatum hydrocortisone acetate/urea hydrocortisone lotion hydrocortisone/aloe gel LOKARA (desonide) PEDIADERM HC (hydrocortisone) PEDIADERM TA (hydrocortisone) SCALPICIN OTC (hydrocortisone) SYNALAR (fluocinolone) TEXACORT (hydrocortisone) VERDESO (desonide)	
GROWTH HORMONE^{CL}			
	GENOTROPIN (somatropin) NORDITROPIN (somatropin) NUTROPIN AQ PENS (somatropin)	HUMATROPE (somatropin) INCRELEX (mecasermin) NUTROPIN (somatropin) NUTROPIN AQ VIALS (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) TEV-TROPIN (somatropin) ZORBTIVE (somatropin)	The preferred agents must be tried before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. Patients already on a non-preferred agent will receive authorization to continue therapy on that agent for the duration of the existing PA.
H. PYLORI COMBINATION TREATMENTS			
	Please use individual components: preferred PPI (Dexilant, omeprazole or pantoprazole) amoxicillin tetracycline metronidazole clarithromycin bismuth chewable tablets, tablets	HELIDAC (bismuth/metronidazole/tetracycline) OMECLAMOX-PAK (omeprazole/amoxicillin/clarithromycin) PREVPAK (lansoprazole/amoxicillin/clarithromycin) PYLERA (bismuth/metronidazole/tetracycline)	A trial of all the individual preferred components (with Dexilant, omeprazole or pantoprazole) at the recommended dosages, frequencies and duration is required before the brand name combination packages will be approved unless one (1) of the exceptions on the PA form is present.
HEPATITIS B TREATMENTS			
	EPIVIR HBV (lamivudine) HEPSERA (adefovir) TYZEKA (telbivudine)	BARACLUDE (entecavir)	A thirty (30) day trial of one (1) of the preferred agents is required before the non-preferred agent will



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			be authorized unless one (1) of the exceptions on the PA form is present.
HEPATITIS C TREATMENTS^{CL}			
	INCIVEK (telaprevir) ^{CL} PEGASYS (pegylated interferon) PEG-INTRON (pegylated interferon) ribavirin VICTRELIS (boceprevir) ^{CL}	COPEGUS (ribavirin) INFERGEN (consensus interferon) REBETOL (ribavirin) RIBAPAK (ribavirin) RIBASPHERE 400mg, 600mg (ribavirin)	Patients starting therapy in this class must try the preferred agent of a dosage form before a non-preferred agent of that dosage form will be authorized. See additional criteria for Incivek and Victrelis at http://www.dhhr.wv.gov/bms/Pharmacy/Pages/pac.aspx
HYPERURICEMIA AND GOUT AGENTS			
ANTIMITOTICS			
		COLCRYS (colchicine)*	A thirty (30) day trial of one (1) of the preferred agents for the prevention of gouty arthritis attacks (colchicine/probenecid, probenecid, or allopurinol) is required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present. *In the case of acute gouty attacks, a ten (10) day supply (twenty (20) tablets) of Colcrys will be approved per ninety 90 days.
ANTIMITOTIC-URICOSURIC COMBINATION			
	colchicine/probenecid		
URICOSURIC			
	probenecid		
XANTHINE OXIDASE INHIBITORS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	allopurinol	ULORIC (febuxostat) ZYLOPRIM (allopurinol)	
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS			
INJECTABLE			
		BYDUREON (exenatide) BYETTA (exenatide) SYMLIN (pramlintide) VICTOZA (liraglutide)	<p>Byetta, Bydureon and Victoza will be authorized for six (6) month intervals if each of the following criteria are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of Type 2 Diabetes and 2. Previous history of a thirty (30) day trial of metformin, unless contraindicated and 3. No history of pancreatitis and 4. For concurrent therapy with insulin, treatment with a bolus insulin is contraindicated. <p>Approval will be given for six (6) month intervals. For re-authorizations, HgBA1C levels must have decreased by at least 1% until levels are ≤8%. HgBA1C levels within ninety (90) days of start date and at the six (6) month interval must be submitted. Further authorizations will be issued for six (6) month intervals. Laboratory work submitted must be for the most recent thirty (30) day period.</p> <p>Symlin will be approved with a history of bolus insulin utilization in the past ninety (90) days with no gaps in insulin therapy greater than thirty (30) days.</p>
ORAL^{AP}			
	JANUMET (sitagliptin/metformin) ^{AP} JANUVIA (sitagliptin) ^{AP} JUVISYNC (sitagliptin/simvastatin) ^{AP} KOMBIGLYZE XR (saxagliptin/metformin) ^{AP}	JANUMET XR (sitagliptin/metformin) JENTADUETO (linagliptin/metformin) KAZANO (alogliptin/metformin) NESINA (alogliptin)	Januvia/Janumet/Juvisync, Onglyza/Kombiglyze XR and Tradjenta will be subject to the following edits:



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ONGLYZA (saxagliptin) ^{AP} TRADJENTA (linagliptin) ^{AP}	OSENI (alogliptin/pioglitazone)	<ol style="list-style-type: none"> 1. Previous history of a thirty (30) day trial of metformin. 2. Januvia / Janumet / Juvisync, Onglyza/Kombiglyze XR and Tradjenta will be approved for concurrent use with insulin for six (6) month intervals. For re-authorization, HgBA1C levels must be less than or equal (≤) to eight percent (8%). Current laboratory values must be submitted. <p>Jentaduetto and Janumet XR will be approved after thirty (30) day trials of the preferred combination agents, Janumet and Kombiglyze XR.</p>
	SGLT2		
		INVOKANA (canagliflozin)^{NR}	
HYPOGLYCEMICS, INSULINS			
	HUMALOG (insulin lispro) HUMALOG PEN/KWIKPEN (insulin lispro) HUMALOG MIX VIALS (insulin lispro/lispro protamine) HUMULIN VIALS (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLIN (insulin) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine)	APIDRA (insulin glulisine) ^{AP} HUMALOG MIX PENS (insulin lispro/lispro protamine) HUMULIN PENS (insulin)	<p>To receive Apidra, patients must meet the following criteria:</p> <ol style="list-style-type: none"> 1. Be four (4) years of age or older; 2. Be currently on a regimen including a longer-acting or basal insulin. 3. Had a trial of a similar preferred agent, Novolog or Humalog, with documentation that the desired results were not achieved. <p>Humulin pens and Humalog Mix pens will be approved only for patients who cannot utilize vials due to impaired vision or dexterity.</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
HYPOGLYCEMICS, MEGLITINIDES			
	MEGLITINIDES		A thirty (30) day trial of a preferred agent is required before a non-preferred agent will be authorized, unless one (1) of the exceptions on the PA form is present.
	PRANDIN (repaglinide) STARLIX (nateglinide)	nateglinide	
	MEGLITINIDE COMBINATIONS		
		PRANDIMET (repaglinide/metformin)	
HYPOGLYCEMICS, MISCELLANEOUS			
	WELCHOL (colesevelam) ^{AP}		Welchol will be approved for add-on therapy for type 2 diabetes when there is a previous history of a thirty (30) day trial of an oral agent (sulfonylurea, thiazolidinedione (TZD) or metformin).
HYPOGLYCEMICS, TZDS^{AP}			
	THIAZOLIDINEDIONES		Treatment naïve patients require a two (2) week trial of Actos before Avandia will be authorized, unless one (1) of the exceptions on the PA form is present.
	pioglitazone	ACTOS (pioglitazone) AVANDIA (rosiglitazone)	
	TZD COMBINATIONS		Patients are required to use the components of Actoplus Met and Duetact separately. Exceptions will be handled on a case-by-case basis.
		ACTOPLUS MET (pioglitazone/ metformin) ACTOPLUS MET XR (pioglitazone/ metformin) AVANDAMET (rosiglitazone/metformin) ^{AP} AVANDARYL (rosiglitazone/glimepiride) ^{AP} DUETACT (pioglitazone/glimepiride) pioglitazone/glimepiride pioglitazone/ metformin	
IMMUNOSUPPRESSIVES			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	azathioprine cyclosporine cyclosporine, modified mycophenolate mofetil RAPAMUNE (sirolimus) tacrolimus	AZASAN (azathioprine) CELLCEPT (mycophenolate mofetil) IMURAN (azathioprine) MYFORTIC (mycophenolic acid) NEORAL (cyclosporine, modified) PROGRAF (tacrolimus) SANDIMMUNE (cyclosporine) ZORTRESS (everolimus)	A fourteen (14) day trial of a preferred agent is required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present (non-preferred agents will be grandfathered for patients currently on these therapies).
IMPETIGO AGENTS (Topical)			
	bacitracin gentamicin sulfate mupirocin ointment	ALTABAX (retapamulin) BACTROBAN (mupirocin) CENTANY (mupirocin) CORTISPORIN (bacitracin/neomycin/polymyxin/HC) mupirocin cream neomycin/polymyxin/pramoxine	Ten (10) day trials of at least one (1) preferred agent, including the generic formulation of a requested non-preferred agent, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
INTRANASAL RHINITIS AGENTS^{AP}			
ANTICHOLINERGICS			
	ipratropium	ATROVENT(ipratropium)	Thirty (30) day trials of the preferred nasal anti-cholinergic, an antihistamine, and corticosteroid groups are required before a non-preferred anti-cholinergic will be approved unless one (1) of the exceptions on the PA form is present.
ANTI HISTAMINES			
	ASTELIN (azelastine) PATANASE (olopatadine)	ASTEPRO (azelastine) azelastine	Thirty (30) day trials of both preferred intranasal antihistamines and a thirty (30) day trial of one (1) of the preferred intranasal corticosteroids are required before the non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
COMBINATIONS			
		DYMISTA (azelastine / fluticasone)	
CORTICOSTEROIDS			
	fluticasone propionate NASACORT AQ (triamcinolone) NASONEX (mometasone)	BECONASE AQ (beclomethasone) FLONASE (fluticasone propionate) flunisolide OMNARIS (ciclesonide) QNASL (beclomethasone) RHINOCORT AQUA (budesonide) triamcinolone VERAMYST (fluticasone furoate) ZETONNA (ciclesonide)	Thirty (30) day trials of each preferred agent in the corticosteroid group are required before a non-preferred corticosteroid agent will be authorized unless one (1) of the exceptions on the PA form is present.
LEUKOTRIENE MODIFIERS			
	ACCOLATE (zafirlukast) montelukast	SINGULAIR (montelukast) zafirlukast ZYFLO (zileuton)	Thirty (30) day trials each of the preferred agents are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
LIPOTROPICS, OTHER (Non-statins)^{AP}			
BILE ACID SEQUESTRANTS			
	cholestyramine colestipol tablets	COLESTID (colestipol) colestipol granules KYNAMRO (mipomersen) ^{NR} QUESTRAN (cholestyramine) WELCHOL (colesevelam)	A twelve (12) week trial of one (1) of the preferred agents is required before a non-preferred agent in the corresponding category will be authorized. Welchol will be approved for add-on therapy for type 2 diabetes when there is a previous history of a thirty (30) day trial of an oral agent (sulfonylurea, thiazolidinedione (TZD) or metformin). See HYPOGLYCEMICS, MISCELLANEOUS.
CHOLESTEROL ABSORPTION INHIBITORS			



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ZETIA (ezetimibe) ^{AP}		Zetia will be approved with prior use of a HMG-CoA reductase inhibitor within the previous six (6) months.
	FATTY ACIDS		
		LOVAZA (omega-3-acid ethyl esters) ^{AP} VASCEPA (icosapent ethyl)	Lovaza and Vascepa will be approved when the patient is intolerant or not responsive to, or not a candidate for nicotinic acid or fibrate therapy.
	FIBRIC ACID DERIVATIVES		
	fenofibrate 54mg & 160mg fenofibrate micronized 67mg, 134mg & 200mg gemfibrozil TRICOR (fenofibrate nanocrystallized) TRILIPIX (fenofibric acid)	ANTARA (fenofibrate) FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) fenofibrate 43mg, 130mg fenofibrate nanocrystallized 48mg, 145mg fenofibric acid LIPOFEN (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRIGLIDE (fenofibrate)	
	NIACIN		
	niacin NIACOR (niacin) NIASPAN (niacin) SLO-NIACIN (niacin)		
LIPOTROPICS, STATINS^{AP}			
	STATINS		
	atorvastatin LESCOL (fluvastatin) LESCOL XL (fluvastatin) lovastatin pravastatin simvastatin ^{CL*}	ALTOPREV (lovastatin) CRESTOR (rosuvastatin) fluvastatin LIPITOR (atorvastatin) LIVALO (pitavastatin) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin) [*]	Twelve (12) week trials each of two (2) of the preferred statins, including the generic formulation of a requested non-preferred agent, are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. *Zocor/simvastatin 80mg tablets will require a clinical PA



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
STATIN COMBINATIONS			
	ADVICOR (lovastatin/niacin) amlodipine / atorvastatin SIMCOR (simvastatin/niacin ER)	CADUET (atorvastatin/amlodipine) LIPTRUZET (atorvastatin/ezetimibe)^{NR} VYTORIN (simvastatin/ ezetimibe)	Vytorin will be approved only after an insufficient response to the maximum tolerable dose of atorvastatin after twelve (12) weeks, unless one (1) of the exceptions on the PA form is present. *Vytorin 80/10mg tablets will require a clinical PA
MACROLIDES/KETOLIDES (Oral)			
KETOLIDES			
		KETEK (telithromycin)	Requests for telithromycin will be authorized if there is documentation of the use of any antibiotic within the past twenty-eight (28) days.
MACROLIDES			
	azithromycin clarithromycin erythromycin base	BIAXIN (clarithromycin) BIAXIN XL (clarithromycin) clarithromycin ER E.E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)	Five (5) day trials each of the preferred agents are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.
MULTIPLE SCLEROSIS AGENTS^{CL, AP}			
INTERFERONS			
	AVONEX (interferon beta-1a) AVONEX PEN (interferon beta-1a)	EXTAVIA (interferon beta-1b)	A thirty (30) day trial of a preferred agent will be required before a non-



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	BETASERON (interferon beta-1b) REBIF (interferon beta-1a) REBIF REBIDOSE (interferon beta-1a)		preferred agent will be approved.
NON-INTERFERONS			
	COPAXONE (glatiramer)	AMPYRA (dalfampridine)* GILENYA (fingolimod) ** AUBAGIO (teriflunomide)*** TECFIDERA (dimethyl fumarate)^{NR}	<p>A thirty (30) day trial of the preferred agent will be required before a non-preferred agent will be approved.</p> <p>*Amypra will be prior authorized if the following conditions are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of multiple sclerosis and 2. No history of seizures and 3. No evidence of moderate or severe renal impairment and 4. Initial prescription will be approved for thirty (30) days only. <p>** Gilenya: PA Criteria</p> <ol style="list-style-type: none"> 1. A diagnosis of a relapsing form of multiple sclerosis and 2. Medication is prescribed by a neurologist and 3. History of a thirty (30) day trial of one (1) of the preferred agents for multiple sclerosis unless one (1) of the exceptions on the PA form is present and 4. Dosage is limited to one (1) tablet per day. (AP does not apply.) <p>*** Aubagio will be authorized if each of the following criteria are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of relapsing multiple sclerosis and



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<ol style="list-style-type: none"> 2. Trial of the preferred first-line agent in each class (interferon and non-interferon) for thirty (30) days each and 3. Measurement of transaminase and bilirubin levels within the (6) months before initiation of therapy and ALT levels at least monthly for six (6) months after initiation of therapy and 4. Complete blood cell count (CBC) within six (6) months before initiation of therapy and 5. Female patients must have a negative pregnancy test before initiation of therapy and be established on a reliable method of contraception if appropriate and 6. Patient is from eighteen (18) up to sixty-five (65) years of age and 7. Negative tuberculin skin test before initiation of therapy
MUSCLE RELAXANTS (Oral)^{AP}			
ACUTE MUSCULOSKELETAL RELAXANT AGENTS			
	chlorzoxazone cyclobenzaprine IR 5, 10 mg methocarbamol	AMRIX (cyclobenzaprine) carisoprodol carisoprodol/ASA carisoprodol/ASA/codeine cyclobenzaprine ER cyclobenzaprine IR 7.5 mg FLEXMID (cyclobenzaprine) FLEXERIL (cyclobenzaprine) LORZONE (chlorzoxazone) metaxalone orphenadrine orphenadrine/ASA/caffeine PARAFON FORTE (chlorzoxazone)	<p>Thirty (30) day trials of the preferred acute musculoskeletal relaxants are required before a non-preferred acute musculoskeletal agent will be approved, with the exception of carisoprodol.</p> <p>Thirty (30) day trials of the preferred acute musculoskeletal relaxants and Skelaxin are required before carisoprodol will be approved.</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		ROBAXIN (methocarbamol) SKELAXIN (metaxalone) SOMA (carisoprodol)	
MUSCULOSKELETAL RELAXANT AGENTS USED FOR SPASTICITY			
	baclofen tizanidine tablets	DANTRIUM (dantrolene) dantrolene tizanidine capsules ZANAFLEX (tizanidine)	Thirty (30) day trials of the preferred skeletal muscle relaxants associated with the treatment of spasticity (are required before non-preferred agents will be approved unless one (1) of the exceptions on the PA form is present.
NEUROPATHIC PAIN			
	capsaicin OTC CYMBALTA (duloxetine) gabapentin LYRICA (pregabalin) ^{AP} SAVELLA (milnacipran) ^{*AP}	GRALISE (gabapentin) HORIZANT (gabapentin) LIDODERM (lidocaine) ^{AP} NEURONTIN (gabapentin) QUTENZA (capsaicin) ZOSTRIX OTC (capsaicin)	Lyrica will be approved for: <ol style="list-style-type: none"> 1. Diagnosis of seizure disorders or neuropathic pain associated with a spinal cord injury or 2. Diagnosis of fibromyalgia, postherpetic neuralgia, or diabetic neuropathy AND a history of a trial of gabapentin at a therapeutic dose range between 900mg and 2,400mg per day for thirty (30) days within the previous twenty-four (24) month period or an intolerance due to a potential adverse drug-drug interaction, drug-disease interaction, or intolerable side effect (In cases of renal impairment, doses may be adjusted based on the



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<p>degree of impairment.)</p> <p>Lidoderm patches will be approved for a diagnosis of post-herpetic neuralgia.</p> <p>* Savella will be approved for a diagnosis of fibromyalgia or a previous thirty (30) day trial of a drug that infers fibromyalgia: gabapentin, Cymbalta, Lyrica, amitriptyline or nortriptyline.</p> <p>Requests for Gralise will be authorized if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Diagnosis of post herpetic neuralgia and 2. Trial of a tricyclic antidepressant for a least thirty (30) days and 3. Trial of gabapentin immediate release formulation (positive response without adequate duration) <p>Request is for once daily dosing with 1800mg. maximum daily dosage.</p>
NSAIDS^{AP}			
	NON-SELECTIVE		
	diclofenac (IR, SR) etodolac IR flurbiprofen ibuprofen (Rx and OTC) INDOCIN SUSPENSION (indomethacin) indomethacin ketorolac naproxen (Rx and OTC) sulindac	ANAPROX (naproxen) ANSAID (flurbiprofen) CAMBIA (diclofenac) CATAFLAM (diclofenac) CLINORIL (sulindac) DAYPRO (oxaprozin) diflunisal DUEXIS (famotidine/ibuprofen) etodolac SR FELDENE (piroxicam) fenoprofen INDOCIN SUPPOSITORIES (indomethacin)	<p>Thirty (30) day trials of each of the preferred agents are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present.</p>



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		indomethacin ER ketoprofen ketoprofen ER meclofenamate mefenamic acid MOTRIN (ibuprofen) nabumetone NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) oxaprozin piroxicam PONSTEL (meclofenamate) SPRIX (ketorolac) tolmetin VOLTAREN (diclofenac) ZIPSOR (diclofenac potassium)	
NSAID/GI PROTECTANT COMBINATIONS			
		ARTHROTEC (diclofenac/misoprostol) diclofenac/misoprostol VIMOVO (naproxen/esomeprazole)	
COX-II SELECTIVE			
	meloxicam	CELEBREX (celecoxib) MOBIC (meloxicam)	Requests for COX-2 Inhibitor agents will be authorized if the following criteria are met: Agent is requested for treatment of a chronic condition and 1. Patient is 70 years of age or older, or 2. Patient is currently on anticoagulation therapy, or 3. Patient has a history or risk of a serious GI complication.
OPHTHALMIC ANTIBIOTICS^{AP}			
	bacitracin/polymyxin ointment ciprofloxacin* erythromycin gentamicin	AZASITE (azithromycin) bacitracin BESIVANCE (besifloxacin) BLEPH-10 (sulfacetamide)	Five (5) day trials of each of the preferred agents are required before non-preferred agents will be authorized unless one (1) of the



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	MOXEZA (moxifloxacin)* ofloxacin* polymyxin/trimethoprim sulfacetamide tobramycin VIGAMOX (moxifloxacin)*	CILOXAN (ciprofloxacin) GARAMYCIN (gentamicin) ILOTYCIN (erythromycin) levofloxacin NATACYN (natamycin) neomycin/bacitracin/polymyxin neomycin/polymyxin/gramicidin NEOSPORIN (neomycin/polymyxin/gramicidin) OCUFLOX (ofloxacin) POLYTRIM (polymyxin/trimethoprim) QUIXIN (levofloxacin) sulfacetamide ointment TOBEX (tobramycin) ZYMAR (gatifloxacin) ZYMAXID (gatifloxacin)	exceptions on the PA form is present. The American Academy of Ophthalmology guidelines on treating bacterial conjunctivitis recommend as first line treatment options: erythromycin ointment, sulfacetamide drops, or polymyxin/trimethoprim drops. *A prior authorization is required for the fluoroquinolone agents for patients up to twenty-one (21) years of age unless there has been a trial of a first line treatment option within the past ten (10) days.
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS			
	BLEPHAMIDE (prednisolone/sulfacetamide) BLEPHAMIDE S.O.P. (prednisolone/sulfacetamide) MAXITROL (neomycin/polymyxin/dexamethasone) neomycin/bacitracin/polymyxin/hydrocortisone neomycin/polymyxin/dexamethasone sulfacetamide/prednisolone TOBRADEX SUSPENSION (tobramycin/dexamethasone)	neomycin/polymyxin/hydrocortisone POLY-PRED (prednisolone/neomycin/polymyxin B) PRED-G (prednisolone/gentamicin) TOBRADEX OINTMENT (tobramycin/dexamethasone) TOBRADEX ST (tobramycin/dexamethasone) tobramycin/dexamethasone suspension ZYLET (loteprednol/tobramycin)	Thirty (30) day trials of each of the preferred agents are required unless one (1) of the exceptions on the PA form is present.
OPHTHALMIC ANTI-INFLAMMATORIES			
	dexamethasone diclofenac fluorometholone flurbiprofen ketorolac NEVANAC (nepafenac) prednisolone acetate	ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac tromethamine) ^{AP} BROMDAY (bromfenac) bromfenac DUREZOL (difluprednate) ^{AP} FLAREX (fluorometholone) FML (fluorometholone) FML FORTE (fluorometholone)	Five (5) day trials of each of the preferred ophthalmic anti-inflammatory agents are required before non-preferred agents will be authorized unless one (1) of the exceptions on the PA form is present.



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		FML S.O.P. (fluorometholone) ILEVRO (nepafenac) LOTEMAX DROPS, OINTMENT (loteprednol) LOTEMAX GEL (loteprednol) MAXIDEX (dexamethasone) OMNIPRED (prednisolone) OZURDEX (dexamethasone) PRED FORTE (prednisolone) PRED MILD (prednisolone) prednisolone sodium phosphate PROLENSA (bromfenac)^{NR} RETISERT (fluocinolone) TRISENCE (triamcinolone) VEXOL (rimexolone) XIBROM (bromfenac)	
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS			
	ALAWAY (ketotifen) ALREX (loteprednol) cromolyn ketotifen PATADAY (olopatadine) PATANOL (olopatadine) ZADITOR OTC (ketotifen) ZYRTEC ITCHY EYE (ketotifen)	ALAMAST (pemirolast) ^{AP} ALOCRIAL (nedocromil) ^{AP} ALOMIDE (lodoxamide) ^{AP} azelastine BEPREVE (bepotastine) ^{AP} CROLOM (cromolyn) ^{AP} ELESTAT (epinastine) ^{AP} EMADINE (emedastine) ^{AP} epinastine LASTACRAFT (alcaftadine) OPTICROM (cromolyn) ^{AP} OPTIVAR (azelastine)	Thirty (30) day trials of each of three (3) of the preferred agents are required before non-preferred agents will be authorized, unless one (1) of the exceptions on the PA form is present.
OPHTHALMICS, GLAUCOMA AGENTS			
COMBINATION AGENTS			
	COMBIGAN (brimonidine/timolol) dorzolamide/timolol	COSOPT (dorzolamide/timolol) COSOPT PF (dorzolamide/timolol) SIMBRINZA (brinzolamide/brimonidine)^{NR}	Authorization for a non-preferred agent will only be given if there is an allergy to the preferred agents.
BETA BLOCKERS			
	BETOPTIC S (betaxolol) carteolol levobunolol metipranolol timolol	BETAGAN (levobunolol) betaxolol BETIMOL (timolol) ISTALOL (timolol) OPTIPRANOLOL (metipranolol) TIMOPTIC (timolol)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CARBONIC ANHYDRASE INHIBITORS			
	AZOPT (brinzolamide) dorzolamide	TRUSOPT (dorzolamide)	
PARASYMPATHOMIMETICS			
	CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) PHOSPHOLINE IODIDE (echothiophate iodide) pilocarpine	ISOPTO CARPINE (pilocarpine) PILOPINE HS (pilocarpine)	
PROSTAGLANDIN ANALOGS			
	latanoprost TRAVATAN/TRAVATAN-Z (travoprost)	LUMIGAN (bimatoprost) RESCULA (unoprostone) ^{NR} travoprost ^{NR} XALATAN (latanoprost) ZIOPTAN (tafluprost)	
SYMPATHOMIMETICS			
	ALPHAGAN P (brimonidine) brimonidine 0.2% dipivefrin	apraclonidine brimonidine 0.15% IOPIDINE (apraclonidine) PROPINE (dipivefrin)	
OTIC ANTIBIOTICS^{AP}			
	CIPRODEX (ciprofloxacin/dexamethasone)* COLY-MYCIN S (colistin/hydrocortisone/ neomycin/thonzonium bromide) CORTISPORIN SOLUTION (neomycin/polymyxin/HC) neomycin/polymyxin/HC solution/suspension ofloxacin	ciprofloxacin CIPRO HC (ciprofloxacin/hydrocortisone) CETRAXAL 0.2% SOLUTION (ciprofloxacin) CORTISPORIN-TC (colistin/hydrocortisone/ neomycin) FLOXIN (ofloxacin)	Five (5) day trials of each of the preferred agents are required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present. *Ciprodex is limited to patients up to nine (9) years of age. Age exceptions will be handled on a case-by-case basis.
PANCREATIC ENZYMES^{AP}			
	CREON PANCRELIPASE 5000 ZENPEP	PANCREAZE PERTZYE ULTRESA	A thirty (30) day trial of a preferred agent is required before a non-preferred agent will be authorized



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		VIOKACE	<p>unless one (1) of the exceptions on the PA form is present.</p> <p>Non-preferred agents will be approved for members with cystic fibrosis.</p>
PARATHYROID AGENTS^{AP}			
	HECTOROL (doxercalciferol) ZEMPLAR (paricalcitol)	SENSIPAR (cinacalcet)	A thirty (30) day trial of a preferred agent will be required before a non-preferred agent will be approved.
PEDICULICIDES/SCABICIDES (Topical)^{AP}			
	permethrin (RX, OTC) pyrethrins-piperonyl butoxide OTC ULESFIA (benzyl alcohol)	EURAX (crotamiton) LICE EGG REMOVER OTC (benzalkonium chloride) lindane malathion NATROBA (spinosad) OVIDE (malathion) SKLICE (ivermectin) spinosad	Trials of the preferred agents (which are age and weight appropriate) are required before non-preferred agents will be approved unless one (1) of the exceptions on the PA form is present.
PHOSPHATE BINDERS^{AP}			
	ELIPHOS (calcium acetate) PHOSLO (calcium acetate) RENAGEL (sevelamer)	calcium acetate FOSRENOL (lanthanum) PHOSLYRA (calcium acetate) RENVELA (sevelamer carbonate)	Thirty (30) day trials of at least two (2) preferred agents are required unless one (1) of the exceptions on the PA form is present.
PLATELET AGGREGATION INHIBITORS^{AP}			
	AGGRENOX (dipyridamole/ASA) cilostazol clopidogrel	BRILINTA (ticagrelor) dipyridamole EFFIENT (prasugrel) PERSANTINE (dipyridamole) PLAVIX (clopidogrel) PLETAL (cilostazol) TICLID (ticlopidine) ticlopidine	<p>A thirty (30) day trial of a preferred agent is required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present.</p> <p>Effient will be approved for acute coronary syndrome when it is to be managed by acute or delayed percutaneous coronary intervention (PCI). Three (3) day emergency supplies of Effient are available</p>



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			when necessary.
PROGESTINS FOR CACHEXIA			
	megestrol	MEGACE (megestrol) MEGACE ES (megestrol)	
PROTON PUMP INHIBITORS^{AP}			
	DEXILANT (dexlansoprazole) omeprazole (Rx) pantoprazole PREVACID SOLUTABS (lansoprazole)*	ACIPHEX (rabeprazole) lansoprazole Rx NEXIUM (esomeprazole) omeprazole/sodium bicarbonate (Rx) PREVACID CAPSULES (lansoprazole) PRILOSEC Rx (omeprazole) PROTONIX (pantoprazole)	Sixty (60) day trials of each of the preferred agents, inclusive of a concurrent thirty (30) day trial at the maximum dose of an H ₂ antagonist are required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present * Prior authorization is required for Prevacid Solutabs for members eight (8) years of age or older.
PSORIATIC AGENTS - TOPICAL			
	calcipotriene solution, ointment CALCITRENE (calcipotriene) DOVONEX (calcipotriene) TAZORAC (tazarotene)	calcipotriene cream calcitriol SORILUX (calcipotriene) TACLONEX (calcipotriene/ betamethasone) VECTICAL (calcitriol)	Thirty (30) day trials of two (2) preferred unique chemical entities are required before non-preferred agents will be approved unless one (1) of the exceptions on the PA form is present.
PULMONARY ANTIHYPERTENSIVES - ENDOTHELIN RECEPTOR ANTAGONISTS^{CL}			
	LETAIRIS (ambrisentan) TRACLEER (bosentan)		Letairis and Tracleer will be approved for a diagnosis of pulmonary arterial hypertension (PAH).
PULMONARY ANTIHYPERTENSIVES – PDE5s^{CL}			
	ADCIRCA (tadalafil) sildenafil	REVATIO IV (sildenafil) REVATIO TABLETS (sildenafil)	
PULMONARY ANTIHYPERTENSIVES – PROSTACYCLINS^{CL}			
	epoprostenol	FLOLAN (epoprostenol)	Ventavis will only be approved for



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	VENTAVIS (iloprost)	REMODULIN (treprostinil sodium) TYVASO (treprostinil) VELETRI (epoprostenol)	the treatment of pulmonary artery hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms. Remodulin and Tyvaso will be approved only after a thirty (30) day trial of Ventavis unless one (1) of the exceptions on the PA form is present.
SEDATIVE HYPNOTICS^{AP}			
BENZODIAZEPINES			
	temazepam 15, 30 mg	DALMANE (flurazepam) DORAL (quazepam) estazolam flurazepam HALCION (triazolam) quazepam ^{NR} RESTORIL (temazepam) temazepam 7.5, 22.5 mg triazolam	Fourteen (14) day trials of the preferred agents in both categories are required before a non-preferred agent will be authorized unless one (1) of the exceptions on the PA form is present. Strengths of zolpidem that are non-preferred (6.25 and 12.5mg) must be created by combining or splitting the preferred doses (5 and 10mg) of zolpidem, if appropriate.
OTHERS			
	zolpidem 5, 10 mg	AMBIEN (zolpidem) AMBIEN CR (zolpidem) chloral hydrate EDLUAR (zolpidem) INTERMEZZO (zolpidem) LUNESTA (eszopiclone) ROZEREM (ramelteon) SILENOR (doxepin) SOMNOTE (chloral hydrate) SONATA (zaleplon) zaleplon zolpidem ER 6.25, 12.5 mg ZOLPIMIST (zolpidem)	
STIMULANTS AND RELATED AGENTS			
AMPHETAMINES			



BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

EFFECTIVE
08/01/13
Version 2013.3f

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	amphetamine salt combination IR dextroamphetamine tablet VYVANSE (lisdexamfetamine)	ADDERALL (amphetamine salt combination) ADDERALL XR (amphetamine salt combination) amphetamine salt combination ER DESOXYN (methamphetamine) DEXEDRINE (dextroamphetamine) dextroamphetamine ER dextroamphetamine solution ^{NR} DEXTROSTAT (dextroamphetamine) methamphetamine PROCENTRA (dextroamphetamine) ZENZEDI (dextroamphetamine) ^{NR}	<p>One of the preferred agents in each group (amphetamines and non-amphetamines) must be tried for thirty (30) days before a non-preferred agent will be authorized. In addition, a long-acting preferred agent in each class must be tried for thirty (30) days before a non-preferred long-acting stimulant will be approved.</p> <p>Except for Strattera, PA is required for adults eighteen (18) years of age or older.</p> <p>Thirty (30) day trials of at least three (3) antidepressants are required before amphetamines will be approved for depression.</p> <p>Provigil will only be approved for patients sixteen (16) years of age or older with a diagnosis of narcolepsy.</p>
NON-AMPHETAMINE			
	DAYTRANA (methylphenidate) FOCALIN (dexmethylphenidate) FOCALIN XR (dexmethylphenidate) guanfacine INTUNIV (guanfacine extended-release) METADATE CD (methylphenidate) METHYLIN CHEWABLE TABLETS, SOLUTION (methylphenidate) methylphenidate methylphenidate ER (generic Concerta, Ritalin SR, Metadate ER, Methylin ER) STRATTERA (atomoxetine)	CONCERTA (methylphenidate) dexmethylphenidate KAPVAY ER (clonidine) METADATE ER (methylphenidate) methylphenidate solution methylphenidate CD methylphenidate ER (generic Ritalin LA) modafinil NUVIGIL (armodafinil) pemoline PROVIGIL (modafinil) QUILLIVANT XR (methylphenidate) RITALIN (methylphenidate) RITALIN LA (methylphenidate) RITALIN SR (methylphenidate)	<p>Strattera will not be approved for concurrent administration with amphetamines or methylphenidates, except for thirty (30) days or less for tapering purposes. Strattera is limited to a maximum of 100mg per day.</p> <p>Kapvay will be approved if the following criteria are met:</p> <ol style="list-style-type: none"> 1. Fourteen (14) day trials of at least one (1) preferred product from the amphetamine and non-amphetamine class and 2. A fourteen (14) day trial of Strattera and 3. A fourteen (14) day trial of clonidine (for Kapvay) unless



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			<p>one (1) of the exceptions on the PA form is present or</p> <p>4. In cases of a diagnosis of Tourette's syndrome, tics, autism or disorders included in the autism spectrum, only a fourteen (14) day trial of clonidine (for Kapvay) is required for approval.</p>
TETRACYCLINES^{AP}			
	<p>doxycycline hyclate capsules, tablets^{CL} doxycycline monohydrate tablet^{CL} minocycline capsules tetracycline</p>	<p>ADOXA (doxycycline monohydrate)^{CL} demeclocycline* DORYX (doxycycline hyclate)^{CL} doxycycline hyclate tablet DR^{CL} doxycycline monohydrate capsule^{CL} doxycycline monohydrate suspension^{CL NR} DYNACIN (minocycline) MINOCIN (minocycline) minocycline ER capsules minocycline tablets MONODOX (doxycycline monohydrate)^{CL} MORGIDOX KIT (doxycycline)^{CL} ORACEA (doxycycline monohydrate)^{CL} SOLODYN (minocycline) VIBRAMYCIN CAPSULES, SUSPENSION, SYRUP (doxycycline)^{CL}</p>	<p>A ten (10) day trial of each of the preferred agents is required before a non-preferred agent will be approved.</p> <p>*Demeclocycline will be approved for conditions caused by susceptible strains of organisms designated in the product information supplied by the manufacturer. A C&S report must accompany this request.</p> <p>*Demeclocycline will also be approved for SIADH.</p> <p>As per the CDC Health Advisory from 6/12/13 on the nationwide shortage of doxycycline, doxycycline will only be approved for any one of the following:</p> <ul style="list-style-type: none"> - treatment of Rickettsial infection (or suspected Rickettsial infection) -prophylaxis of Lyme Disease -treatment of Lyme Disease in patients with known penicillin/cephalosporin allergy -prophylaxis and treatment of malaria -treatment of STDs in patients with trial and failure, contraindication,



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID**

PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
			drug-drug interaction to alternative therapies
ULCERATIVE COLITIS AGENTS^{AP}			
ORAL			
	APRISO (mesalamine) ASACOL (mesalamine) 400mg balsalazide DELZICOL (mesalamine) DIPENTUM (olsalazine) PENTASA (mesalamine) 250mg sulfasalazine	ASACOL HD (mesalamine) AZULFIDINE (sulfasalazine) COLAZAL (balsalazide) GIAZO (balsalazide) LIALDA (mesalamine) PENTASA (mesalamine) 500mg	Thirty (30) day trials of each of the preferred agents of a dosage form must be tried before a non-preferred agent of that dosage form will be authorized unless one (1) of the exceptions on the PA form is present.
RECTAL			
	CANASA (mesalamine) mesalamine	mesalamine kit ROWASA (mesalamine) SF ROWASA (mesalamine)	
VAGINAL ANTIBACTERIALS			
	clindamycin cream METROGEL (metronidazole)	AVC (sulfanilamide) CLEOCIN CREAM (clindamycin) CLEOCIN OVULE (clindamycin) CLINDESSE (clindamycin) metronidazole VANDAZOLE (metronidazole)	A trial, the duration of the manufacturer's recommendation, of each of the preferred agents is required before a non-preferred agent will be approved unless one (1) of the exceptions on the PA form is present.
MISC BRAND/GENERIC			
CLONIDINE			
	CATAPRES-TTS (clonidine) clonidine tablets	clonidine patch NEXICLON XR (clonidine) CATAPRES TABLETS (clonidine)	A thirty (30) day trial of each preferred unique chemical entity in the corresponding therapeutic category is required before a non-preferred agent will be authorized.
SUBLINGUAL NITROGLYCERIN			
	nitroglycerin sublingual NITROLINGUAL SPRAY (nitroglycerin) NITROSTAT SUBLINGUAL (nitroglycerin)	nitroglycerin spray NITROMIST (nitroglycerin)	



**BUREAU FOR MEDICAL SERVICES
WEST VIRGINIA MEDICAID
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE
08/01/13
Version 2013.3f**

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SUBSTANCE ABUSE TREATMENTS			
	SUBOXONE FILM (buprenorphine/naloxone) ^{CL}	SUBOXONE TABLETS (buprenorphine/naloxone) buprenorphine/naloxone tablets	Suboxone PA criteria is available at http://www.dhhr.wv.gov/bms/Pharmacy/Pages/pac.aspx